The FDA needs to set standards for using artificial intelligence in drug development
Author
Charles K. Fisher
Published
November 7, 2019
Opinion: Poorly constructed AI algorithms for drug discovery and testing have the potential to cause harm. The FDA should play an important role in ensuring that AI-based drug development tools meet appropriate standards.
Charles Fisher, Unlearn.AI: “now is the time to adopt AI-based solutions”
August 7, 2022
The potential for AI implementation in healthcare can barely be measured, as it can already do what humans do, just countless times better and more efficiently.
